N@N

WARNER CHILCOTT PLC-CLASS A (NASDAQ:WCRX), Up By 8.70% ($1.93) From $22.190 After BUYINS.NET Report Predicted Strength After Ea

^{Published on 2011-05-11 08:12:27 - WOPRAI}
 

May 10, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Thursday, May 5th 2011 stating that WARNER CHILCOTT PLC-CLASS A (NASDAQ:WCRX) was expected to be Up After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=wcrx&id=164749

At the time this story was written, WARNER CHILCOTT PLC-CLASS A (NASDAQ:WCRX) is Up By 8.70% ($1.93) From $22.190 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

WARNER CHILCOTT PLC-CLASS A (NASDAQ:WCRX) - Warner Chilcott plc, a specialty pharmaceutical company, focuses on the development, manufacture, and promotion of branded pharmaceutical products in gastroenterology, womens healthcare, dermatology, and urology segments in North America and western Europe markets. The company primarily offers ASACOL for the treatment of ulcerative colitis for orally administered 5-aminosalicylic acid products; ASACOL HD that provides dosing advantages for patients in the treatment of moderately active ulcerative colitis; ACTONEL for the prevention and treatment of postmenopausal osteoporosis; FEMCON Fe, OVCON 35, OVCON 50, and ESTROSTEP Fe, which are oral contraceptives for the prevention of pregnancy; ESTRACE cream for treatment of urogenital symptoms of menopause; and FEMHRT, a systemic therapy for the treatment of menopausal symptoms. It also provides DORYX, a tetracycline-class oral antibiotic for the treatment of severe acne; and ENABLEX for the treatment of symptoms of overactive bladder. The company markets its products and services through wholesale pharmaceutical distributors, and retail drug and grocery store chains. The company was founded in 1968 and is based in Dublin, Ireland.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. WARNER CHILCOTT PLC-CLASS A (NASDAQ:WCRX) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net